Clinical Trial Update: A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults [Phase 1]

View source ↗

Summary

Pfizer's Phase 1 safety, tolerability, and pharmacokinetics trial of PF-05180999 in healthy adults for migraine was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• PF-05180999

Snippet

Sponsor: Pfizer | Conditions: Migraine | Phase 1 | Status: WITHDRAWN